Lexicon Pharmaceuticals Inc [NASDAQ: LXRX] stock went on an upward path that rose over 7.14% on Wednesday, amounting to a one-week price increase of more than 3.12%.
Over the last 12 months, LXRX stock dropped by -32.38%. The one-year Lexicon Pharmaceuticals Inc stock forecast points to a potential upside of 70.9. The average equity rating for LXRX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $406.30 million, with 244.92 million shares outstanding and 239.55 million shares in the current float. Compared to the average trading volume of 4.54M shares, LXRX stock reached a trading volume of 7057704 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Lexicon Pharmaceuticals Inc [LXRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LXRX shares is $5.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LXRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for Lexicon Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 30, 2024. While these analysts kept the previous recommendation, Jefferies raised their target price to Hold. The new note on the price target was released on March 07, 2023, representing the official price target for Lexicon Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $10, while Piper Sandler analysts kept a Overweight rating on LXRX stock.
The Average True Range (ATR) for Lexicon Pharmaceuticals Inc is set at 0.16, with the Price to Sales ratio for LXRX stock in the period of the last 12 months amounting to 335.78. The Price to Book ratio for the last quarter was 4.34, with the Price to Cash per share for the same quarter was set at 0.69.
LXRX Stock Performance Analysis:
Lexicon Pharmaceuticals Inc [LXRX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.12. With this latest performance, LXRX shares dropped by -25.34% in over the last four-week period, additionally plugging by 37.50% over the last 6 months – not to mention a drop of -32.38% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LXRX stock in for the last two-week period is set at 39.81, with the RSI for the last a single of trading hit 41.92, and the three-weeks RSI is set at 41.38 for Lexicon Pharmaceuticals Inc [LXRX]. The present Moving Average for the last 50 days of trading for this stock 2.1353, while it was recorded at 1.5740 for the last single week of trading, and 1.6791 for the last 200 days.
Insight into Lexicon Pharmaceuticals Inc Fundamentals:
Lexicon Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.58 and a Current Ratio set at 5.60.
Lexicon Pharmaceuticals Inc [LXRX] Institutonal Ownership Details
The top three institutional holders of LXRX stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in LXRX stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in LXRX stock with ownership which is approximately 5.8386%.
